Condrosulf (chondroitin sulfate) / IBSA Institute Biochemical SA, Pierre Fabre - LARVOL DELTA

Study on Structum® in Adult Patients With Osteoarthritis (TRUST) (clinicaltrials.gov) - P=N/A | N=151 | Completed | Sponsor: Pierre Fabre Medicament | Active, not recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. (PubMed, Aging Clin Exp Res) - "This article aims to review the evidence for the role of highly purified (hp) CS (Condrosulf, IBSA) in the treatment of OA...Full safety reports' analyses confirm that CS is safe to use and has almost no side effects, in particular, it showed better gastrointestinal tolerance if compared with non-steroidal anti-inflammatory drugs (NSAIDs). Moreover, the therapeutic strategy has proved to be cost-effective: treatment with CS reduced the use of NSAIDs and their side effects."

Clinical • HEOR • Journal • Review • Immunology • Musculoskeletal Diseases • Osteoarthritis • Pain • Rheumatology

European chondroitin sulfate and glucosamine food supplements: A systematic quality and quantity assessment compared to pharmaceuticals. (PubMed, Carbohydr Polym) - "Most of the samples (over 19 out of 25) showed lower condroitin sulfate and glucosamine contents than the declared ones (up to -60.3%) while all of them showed a KS contamination (up to 47.1%). Mixed animal origin chondroitin sulfate and multiple molecular weight species were determined in more than 32% of the samples. Only 1 on 5 biologically screened samples had an effective action in vitro almost comparable to the pharmaceuticals."

Journal

Production and application of 3-phosphoadenosine-5- phosphosulfate (PubMed, Sheng Wu Gong Cheng Xue Bao) - "Up to now, the synthesis of PAPS is still too expensive for industrial applications. This review focuses on the recent progress of PAPS production and summaries the application of PAPS, particularly in the production of glucosinolate, heparin, condroitin sulfate, and oxamniquine production."

Journal